About Exact Sciences Corporation - Common Stock (EXAS)
Exact Sciences is a biotechnology company focused on the development and commercialization of innovative cancer screening and diagnostic solutions. With a primary emphasis on early detection, the company aims to improve patient outcomes through advanced molecular tests, including non-invasive tests that help identify colorectal cancer and other cancers at an early stage. Exact Sciences combines sophisticated technology, rigorous scientific research, and a commitment to patient care to provide healthcare providers and patients with critical information that can lead to timely interventions and better health management. Read More
Stability is great, but low-volatility stocks may struggle to deliver market-beating returns over time as they sometimes underperform during bull markets.
Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, today announced it will present ten abstracts at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place May 30–June 3, 2025, in Chicago, Ill. Presentations include new data on the Oncodetect™ molecular residual disease (MRD) test, multi-cancer early detection (MCED) testing, the Oncotype DX Breast Recurrence Score® test, and the Cologuard® test that underscore Exact Sciences’ expanding portfolio and commitment to advancing care through scientific excellence.
Diagnostic company Exact Sciences Corporation (NASDAQ:EXAS) announced better-than-expected revenue in Q1 CY2025, with sales up 10.9% year on year to $706.8 million. The company’s full-year revenue guidance of $3.1 billion at the midpoint came in 1.3% above analysts’ estimates. Its non-GAAP loss of $0.21 per share was significantly below analysts’ consensus estimates.
Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. But speed bumps such as inventory destockings have persisted in the wake of COVID-19,
and over the past six months, the industry has pulled back by 6.7%. This drop was discouraging since the S&P 500 held steady.
Exact Sciences (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, announced today that it has been certified as a 2025 Great Place To Work® for the seventh consecutive year in the U.S., and for the first time in the U.K., Japan, Canada, France, Italy, Poland, and Germany.
Top performing large-cap stocks in the last week: DUOL, CRWV, THC, CARR, SMMT, AUR, ANET, TT, DXCM, XPO. Most had positive financial results and raised guidance.
Shares of diagnostic company Exact Sciences Corporation (NASDAQ:EXAS)
jumped 15.2% in the morning session after the company reported strong first quarter 2025 results which beat analysts' revenue and EBITDA expectations and included full-year revenue guidance that slightly exceeded Wall Street's estimates. Sales grew 11% from the previous year, driven by a 14% rise in screening revenue, while precision oncology grew more modestly at 4% on a core basis. The sales bump largely came from the expansion of the company's test menu and stronger execution in its commercial teams. Overall, this print had some key positives.
Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that company management will participate in the following conference and invited investors to participate by webcast.
Diagnostic company Exact Sciences Corporation (NASDAQ:EXAS) beat Wall Street’s revenue expectations in Q1 CY2025, with sales up 10.9% year on year to $706.8 million. The company’s full-year revenue guidance of $3.10 billion at the midpoint came in 1.3% above analysts’ estimates. Its non-GAAP loss of $0.21 per share was significantly below analysts’ consensus estimates.
Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the Company generated revenue of $707 million for the first quarter ended March 31, 2025, compared to $638 million for the same period of 2024.
Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, today announced the company will present 15 abstracts during Digestive Disease Week (DDW) 2025, taking place May 3-6, 2025, in San Diego, California. The abstracts demonstrate high adherence and strong predicted preference for the Cologuard® test along with abstracts on additional screening programs under development. The abstracts focused on the Cologuard test include data from more than half a million patients. DDW is the premier meeting for professionals working in gastroenterology, hepatology, GI endoscopy, and gastrointestinal surgery. DDW will make abstracts available on their website on May 3.
What a brutal six months it’s been for Exact Sciences. The stock has dropped 37.2% and now trades at $44.10, rattling many shareholders. This may have investors wondering how to approach the situation.
Patients who test positive for circulating tumor DNA with the Oncodetect test during surveillance are 50 times more likely to experience cancer recurrence than those with negative results, the company said.
Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced the launch of Oncodetect™—a new test designed to detect molecular residual disease (MRD) across multiple solid tumors. The Oncodetect test provides patients and their healthcare providers with the insights needed to make more informed decisions throughout the treatment process, advancing the field of MRD testing.
Earnings results often indicate what direction a company will take in the months ahead. With Q4 behind us, let’s have a look at Exact Sciences (NASDAQ:EXAS) and its peers.
Looking back on immuno-oncology stocks’ Q4 earnings, we examine this quarter’s best and worst performers, including Regeneron (NASDAQ:REGN) and its peers.
